RE:RE:RE:RE:Type C Meeting TimingsSo there it appears to be Notable. Type C meeting about "Early consultation on use of biomarker as surrogate end point.....". AWARE study suggested PFS of individuals with biomarker at about 70% an awesome response rate, a paradigm shift in therapeutic. For Bracelet, we must subtract 50% from the AWARE observed PFS of 70% to determine those who can be effectively treated with Pela combination. A large portion of patients with strongest response to Pela withdrew. Recall symptoms of those withdrawing could have been treated effectively with Tylenol per key opinion leaders remarks. The adjusted PFS for bracelet PFS of 35% isnt very useful, and it's likely why ONC never reported biomarker stats for bracelet. I imagine the type C meeting discussions has alot to do with this. My apologies if I screwed this analysis. Remarks welcomed.